P1.08-079 Sulvage Surgery after Definitive Radiotherapy or Chemoradiotherapy for Lung Cancer

Yamasaki, Naoya; Tsuchiya, Tomoshi; Matsumoto, Keitaro; Miyazaki, Takuro; Kamohara, Ryotaro; Obata, Tomohiro; Taniguchi, Daisuke; Yamasaki, Takuya; Nakamura, Daisuke; Tabata, Kazuhiro; Nagayasu, Takeshi

doi:10.1016/j.jtho.2016.11.1046

Cited by 1 publication

(4 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“… 17 Overall, one study reported ‘no severe adhesions’. 19 In two studies, it was reported that adhesions necessitated conversion in one patient each from minimally invasive to open surgery, 15 , 17 and in one study a patient required a partial chest wall resection due to adhesions. 17 Where described, prolonged air leak was reported in: 9.5% (MD Anderson patients, including patients undergoing salvage after SBRT for metastasis), 13 11%, 18 and 25% of patients.…”

Section: Resultsmentioning

confidence: 99%

“… 14 There was one patient that was reported to have died from postoperative complications (acute respiratory distress syndrome and multiple organ failure) after bilobectomy with pulmonary arterial patch angioplasty, 13 and one patient died of respiratory failure, 103 days postsurgery. 19 …”

Section: Resultsmentioning

confidence: 99%

“…Finally, seven suitable articles remained, representing 47 patients. [13][14][15][16][17][18][19] The key data are summarized in Table 1. All were retrospective case series.…”

Section: Resultsmentioning

confidence: 99%

“…Yamasaki 19 3 Not reported COPD, chronic obstructive pulmonary disease; DLCO, diffusion capacity; FEV 1 , forced expiratory volume in 1 second; NSCLC, non-small cell lung cancer.…”

Section: Number Of Patientsmentioning

confidence: 99%

See 3 more Smart Citations

Salvage surgery for local recurrence after stereotactic body radiotherapy for early stage non-small cell lung cancer: a systematic review

et al. 2018

View full text Add to dashboard Cite

Introduction:Stereotactic body (or ablative) radiotherapy (SBRT/SABR) is now a guideline-recommended treatment for medically inoperable patients with peripherally-located, stage I non-small cell lung cancer (NSCLC), and for medically operable patients who decline surgery. The 5-year local failure rate after SBRT is about 10% and in highly selected patients, surgery has been used as a salvage therapy. We performed a systematic review to address the feasibility, safety, and outcome of salvage surgery for locally recurrent early stage NSCLC after SBRT.Methods:A systematic literature search was performed according to Preferred Reporting Items for Systematic Reviews and Meta-Analysis (PRISMA) guidelines. PubMed, Embase and Cochrane databases were searched and two authors independently assessed the articles. A total of seven eligible articles were identified.Results:All seven articles were retrospective case series, representing a total of 47 patients. Surgery was completed in all patients. Where reported in sufficient detail, morbidity (four studies) was between 29 and 50% (series of two patients) and 90-day mortality (six studies) was between 0% (four studies) and 11% (n = 1, disease progression). Median (n = 5)/mean (n = 1) reported or calculated follow ups were 7–54.5/17.3 months. Median overall survival was reported in three studies and ranged between 13.6–82.7 months. Crude survival in three others was 2–35 months.Conclusion:Limited, low-level evidence prevents firm conclusions, but based on the existing data, salvage surgery after local recurrence of NSCLC following SBRT appears technically feasible, with acceptable morbidity and mortality in appropriately selected and counselled patients who are fit enough and who accept the risks (level of evidence 4, strength of recommendation C).

show abstract

Section: Resultsmentioning

confidence: 99%

Section: Resultsmentioning

confidence: 99%

“…Finally, seven suitable articles remained, representing 47 patients. [13][14][15][16][17][18][19] The key data are summarized in Table 1. All were retrospective case series.…”

Section: Resultsmentioning

confidence: 99%

“…Yamasaki 19 3 Not reported COPD, chronic obstructive pulmonary disease; DLCO, diffusion capacity; FEV 1 , forced expiratory volume in 1 second; NSCLC, non-small cell lung cancer.…”

Section: Number Of Patientsmentioning

confidence: 99%

See 2 more Smart Citations